A breath test would be less invasive than the traditional method of using mucus or phlegm samples from the lungs of cystic ...

Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration has ...

The firm will develop an assay to detect and monitor Pseudomonas aeruginosa infection in patients with cystic fibrosis.

BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b ...

Some notoriously difficult to treat infections may not be as resistant to antibiotics as has been thought, according to new research using a microfluidic device that more closely duplicates the fluid ...